降钙素原指导减少脓毒症长期感染相关不良事件:一项随机试验
该多中心随机试验纳入266例符合Sepsis-3定义的脓毒症患者,感染来源为下呼吸道感染、急性肾盂肾炎或原发性血流感染,1:1随机分为降钙素原(PCT)引导停药组与标准治疗组。停药标准为第5天或以后PCT水平较峰值下降≥80%或任何PCT≤0.5 μg/L。PCT组180天感染相关不良事件发生率为7.2%(9/125),标准治疗组为15.3%(20/131),风险比0.45(95%CI 0.20-0.98,P=0.045);28天死亡率分别为15.2%(19/125)与28.2%(37/131),风险比0.51(95%CI 0.29-0.89,P=0.02);抗菌治疗中位疗程分别为5天(范围5-7天)与10天(范围7-15天),P<0.001;PCT组住院费用亦降低。
要点
- 脓毒症患者采用PCT引导停药(第5天或以后PCT下降≥80%或PCT≤0.5 μg/L)可使180天感染相关不良事件从15.3%降至7.2%(HR 0.45,95%CI 0.20-0.98,P=0.045)。
- PCT引导组28天死亡率为15.2%,标准治疗组为28.2%(HR 0.51,95%CI 0.29-0.89,P=0.02)。
- PCT引导组抗菌治疗中位疗程为5天(范围5-7天),标准治疗组为10天(范围7-15天),P<0.001。
- PCT引导组住院费用亦降低。
适用人群与场景
- 符合Sepsis-3定义的脓毒症患者,感染来源为下呼吸道感染、急性肾盂肾炎或原发性血流感染。
诊断标准与关键阈值
- 停药标准:第5天或以后PCT水平较峰值下降≥80%,或任何PCT≤0.5 μg/L。
处置流程与药物剂量
- PCT引导组按上述停药标准停用抗菌药物;标准治疗组按常规治疗。
研究设计与关键结果
- 多中心随机试验,266例脓毒症患者1:1随机分为PCT引导停药组与标准治疗组。
- 180天感染相关不良事件(艰难梭菌(Clostridioides difficile)或多重耐药菌引起的新发感染,或归因于基线艰难梭菌或多重耐药菌感染的死亡)发生率:PCT组7.2%(95%CI 3.8-13.1%;9/125) vs 标准治疗组15.3%(95%CI 10.1-22.4%;20/131),HR 0.45(95%CI 0.20-0.98;P=0.045)。
- 28天死亡率:PCT组15.2%(95%CI 10-22.5%;19/125) vs 标准治疗组28.2%(95%CI 21.2-36.5%;37/131),HR 0.51(95%CI 0.29-0.89;P=0.02)。
- 抗菌治疗中位疗程:PCT组5天(范围5-7天) vs 标准治疗组10天(范围7-15天),P<0.001。
- PCT组住院费用亦降低。
证据类型、等级与局限
- 研究类型:多中心随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在符合Sepsis-3定义、感染来源为下呼吸道感染、急性肾盂肾炎或原发性血流感染的脓毒症患者中,可按第5天或以后PCT下降≥80%或PCT≤0.5 μg/L的标准停用抗菌药物,以缩短抗菌疗程并降低180天感染相关不良事件与28天死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Although early antimicrobial discontinuation guided by procalcitonin (PCT) has shown decreased antibiotic consumption in lower respiratory tract infections, the outcomes in long-term sepsis sequelae remain unclear.Objectives: To investigate if PCT guidance may reduce the incidence of long-term infection-associated adverse events in sepsis.Methods: In this multicenter trial, 266 patients with sepsis (by Sepsis-3 definitions) with lower respiratory tract infections, acute pyelonephritis, or primary bloodstream infection were randomized (1:1) to receive either PCT-guided discontinuation of antimicrobials or standard of care. The discontinuation criterion was ≥80% reduction in PCT levels or any PCT ≤0.5 μg/L at Day 5 or later. The primary outcome was the rate of infection-associated adverse events at Day 180, a composite of the incidence of any new infection by Clostridioides difficile or multidrug-resistant organisms, or any death attributed to baseline C. difficile or multidrug-resistant organism infection. Secondary outcomes included 28-day mortality, length of antibiotic therapy, and cost of hospitalization.Measurements and Main Results: The rate of infection-associated adverse events was 7.2% (95% confidence interval [CI], 3.8-13.1%; 9/125) versus 15.3% (95% CI, 10.1-22.4%; 20/131) (hazard ratio, 0.45; 95% CI, 0.20-0.98; P = 0.045); 28-day mortality 15.2% (95% CI, 10-22.5%; 19/125) versus 28.2% (95% CI, 21.2-36.5%; 37/131) (hazard ratio, 0.51; 95% CI, 0.29-0.89; P = 0.02); and median length of antibiotic therapy 5 (range, 5-7) versus 10 (range, 7-15) days (P < 0.001) in the PCT and standard-of-care arms, respectively. The cost of hospitalization was also reduced in the PCT arm.Conclusions: In sepsis, PCT guidance was effective in reducing infection-associated adverse events, 28-day mortality, and cost of hospitalization.Clinical trial registered with www.clinicaltrials.gov (NCT03333304).
参考来源
- Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial. Am J Respir Crit Care Med. 2021. PMID: 32757963. doi:10.1164/rccm.202004-1201OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。